The inability to remember recent events, process new information, or complete even the most basic of tasks is a hallmark of Alzheimer__ampersandsignrsquo;s disease, an irreversible neurodegenerative brain illness. Among those 65 and older, it is the leading cause of dementia. When a person__ampersandsignrsquo;s cognitive and behavioural skills deteriorate to the point that they become a burden in everyday life, we say that they have dementia.There is currently no known way to halt the progression of AD or stop its symptoms from occurring. Huge literature survey was conducted from various popular medical databases such as Google Scholar, PubMed, ScienceDirect, etc. through the internet and the available data were classified according to their targets.The article focuses on basics of AD, History, Symptoms, Stages, Beta-amyloid peptide, Modulators of amyloid aggregation, Amyloid beta-oligomer, Targets for inhibiting the __ampersandsignbeta;-amyloid production (Monoclonal antibodies, Hormones, Inhibition of A__ampersandsignbeta;-peptide formation, Inhibition of A__ampersandsignbeta;-peptide formation [molecules like Posiphen, JNJ-54861911, LY3202626, E2609, AZD-3293, CNP520, MK-8931, LY2886721, and LY2811376],and Clearance of A__ampersandsignbeta;), and List of beta-amyloid inhibitors in clinical trials.This literature evidences may be a convenient reference (particularly, the low molecular-weight inhibitors) to the modern-day researchers (pharmacognosists, pharmacologists, clinicians, medicinal chemists, medical practitioners, scientists, etc.) working dedicatedly in AD research.This study will certainly open novel avenues for ligand development and revolutionary applications in pharmacotherapeutics.